TY - JOUR
T1 - Risk factors, prevention and treatment of weight gain associated with the use of antidepressants and antipsychotics
T2 - a state-of-the-art clinical review
AU - Solmi, Marco
AU - Miola, Alessandro
AU - Capone, Federico
AU - Pallottino, Simone
AU - Højlund, Mikkel
AU - Firth, Joseph
AU - Siskind, Dan
AU - Holt, Richard I G
AU - Corbeil, Olivier
AU - Cortese, Samuele
AU - Dragioti, Elena
AU - Du Rietz, Ebba
AU - Nielsen, René Ernst
AU - Nordentoft, Merete
AU - Fusar-Poli, Paolo
AU - Hartman, Catharina A
AU - Høye, Anne
AU - Koyanagi, Ai
AU - Larsson, Henrik
AU - Lehto, Kelli
AU - Lindgren, Peter
AU - Manchia, Mirko
AU - Skonieczna-Żydecka, Karolina
AU - Stubbs, Brendon
AU - Vancampfort, Davy
AU - Vieta, Eduard
AU - Taipale, Heidi
AU - Correll, Christoph U
AU - ECNP Physical And meNtal Health Thematic Working Group (PAN-Health)
PY - 2024/10
Y1 - 2024/10
N2 - INTRODUCTION: People with severe mental illness have poor cardiometabolic health. Commonly used antidepressants and antipsychotics frequently lead to weight gain, which may further contribute to adverse cardiovascular outcomes.AREAS COVERED: We searched MEDLINE up to April 2023 for umbrella reviews, (network-)meta-analyses, trials and cohort studies on risk factors, prevention and treatment strategies of weight gain associated with antidepressants/antipsychotics. We developed 10 clinical recommendations.EXPERT OPINION: To prevent, manage, and treat antidepressant/antipsychotic-related weight gain, we recommend i) assessing risk factors for obesity before treatment, ii) monitoring metabolic health at baseline and regularly during follow-up, iii) offering lifestyle interventions including regular exercise and healthy diet based on patient preference to optimize motivation, iv) considering first-line psychotherapy for mild-moderate depression and anxiety disorders, v)choosing medications based on medications' and patient's weight gain risk, vi) choosing medications based on acute vs long-term treatment, vii) using effective, tolerated medications, viii) switching to less weight-inducing antipsychotics/antidepressants where possible, ix) using early weight gain as a predictor of further weight gain to inform the timing of intervention/switch options, and x) considering adding metformin or glucagon-like peptide-1 receptor agonists, or topiramate(second-line due to potential adverse cognitive effects) to antipsychotics, or aripiprazole to clozapine or olanzapine.
AB - INTRODUCTION: People with severe mental illness have poor cardiometabolic health. Commonly used antidepressants and antipsychotics frequently lead to weight gain, which may further contribute to adverse cardiovascular outcomes.AREAS COVERED: We searched MEDLINE up to April 2023 for umbrella reviews, (network-)meta-analyses, trials and cohort studies on risk factors, prevention and treatment strategies of weight gain associated with antidepressants/antipsychotics. We developed 10 clinical recommendations.EXPERT OPINION: To prevent, manage, and treat antidepressant/antipsychotic-related weight gain, we recommend i) assessing risk factors for obesity before treatment, ii) monitoring metabolic health at baseline and regularly during follow-up, iii) offering lifestyle interventions including regular exercise and healthy diet based on patient preference to optimize motivation, iv) considering first-line psychotherapy for mild-moderate depression and anxiety disorders, v)choosing medications based on medications' and patient's weight gain risk, vi) choosing medications based on acute vs long-term treatment, vii) using effective, tolerated medications, viii) switching to less weight-inducing antipsychotics/antidepressants where possible, ix) using early weight gain as a predictor of further weight gain to inform the timing of intervention/switch options, and x) considering adding metformin or glucagon-like peptide-1 receptor agonists, or topiramate(second-line due to potential adverse cognitive effects) to antipsychotics, or aripiprazole to clozapine or olanzapine.
KW - Obesity
KW - antidepressant
KW - antipsychotic
KW - bipolar disorder
KW - depression
KW - psychiatry
KW - safety
KW - schizophrenia
KW - weight gain
UR - http://www.scopus.com/inward/record.url?scp=85204711879&partnerID=8YFLogxK
U2 - 10.1080/14740338.2024.2396396
DO - 10.1080/14740338.2024.2396396
M3 - Review
C2 - 39225182
SN - 1474-0338
VL - 23
SP - 1249
EP - 1269
JO - Expert Opinion on Drug Safety
JF - Expert Opinion on Drug Safety
IS - 10
ER -